908 Devices Inc. (NASDAQ:MASS) Receives Consensus Rating of “Moderate Buy” from Analysts

908 Devices Inc. (NASDAQ:MASS) has earned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $8.00.

A number of brokerages have recently weighed in on MASS. Wall Street Zen raised shares of 908 Devices from a “sell” rating to a “hold” rating in a research note on Monday, September 15th. Leerink Partners upgraded shares of 908 Devices from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a report on Tuesday, August 5th. Leerink Partnrs upgraded shares of 908 Devices from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a research report on Wednesday, October 8th.

908 Devices Trading Down 5.4%

Shares of 908 Devices stock opened at $8.30 on Thursday. The company has a 50-day moving average of $7.20 and a two-hundred day moving average of $6.42. 908 Devices has a 12-month low of $1.81 and a 12-month high of $9.34. The stock has a market cap of $297.64 million, a PE ratio of -15.37 and a beta of 0.46.

908 Devices (NASDAQ:MASS) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The firm had revenue of $4.70 million during the quarter, compared to analyst estimates of $12.17 million. 908 Devices had a negative return on equity of 24.30% and a negative net margin of 30.54%. 908 Devices has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that 908 Devices will post -1.99 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Joseph H. Iv Griffith sold 5,000 shares of the stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $7.07, for a total transaction of $35,350.00. Following the transaction, the chief financial officer directly owned 97,930 shares in the company, valued at approximately $692,365.10. This represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 10,000 shares of company stock valued at $80,593 in the last ninety days. Corporate insiders own 23.70% of the company’s stock.

Institutional Investors Weigh In On 908 Devices

Several hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC purchased a new position in shares of 908 Devices in the 3rd quarter worth $28,000. Nisa Investment Advisors LLC increased its stake in 908 Devices by 453.2% during the second quarter. Nisa Investment Advisors LLC now owns 3,784 shares of the company’s stock worth $27,000 after acquiring an additional 3,100 shares during the last quarter. ANTIPODES PARTNERS Ltd increased its position in 908 Devices by 49.7% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,558 shares of the company’s stock worth $47,000 after purchasing an additional 2,176 shares in the last quarter. Raymond James Financial Inc. purchased a new position in 908 Devices in the second quarter valued at approximately $48,000. Finally, CWM LLC lifted its position in 908 Devices by 541.2% during the first quarter. CWM LLC now owns 6,963 shares of the company’s stock valued at $31,000 after buying an additional 5,877 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.